Arriving in the landscape of obesity management, retatrutide presents a unique method. Unlike many existing medications, retatrutide operates as a twin agonist, at once engaging both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) sensors. This dual stimulation encourages multiple beneficial effects, including